Clinical Trial Update: Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old [Phase 3]

View source ↗

Summary

A Phase 3, double-blind, randomized, placebo-controlled trial of ganaxolone in children aged 6 months to under 2 years with CDKL5 deficiency disorder, sponsored…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cdkl5 Deficiency Disorder

Drugs mentioned

• ganaxolone (ganaxolone)

Snippet

Sponsor: Immedica Pharma AB | Conditions: CDKL5 Deficiency Disorder | Phase 3 | Status: NOT_YET_RECRUITING